trending Market Intelligence /marketintelligence/en/news-insights/trending/DxrslKutR7qgZEc4Kf8RBQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

CTD Holdings medicine secures rare pediatric disease designation from US FDA

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


CTD Holdings medicine secures rare pediatric disease designation from US FDA

CTD Holdings, Inc. secured a rare pediatric disease designation for Trappsol Cyclo from the U.S. Food and Drug Administration.

The medication is used in the treatment of a rare and fatal genetic disease, Niemann-Pick type C, that affects the brain, lung, liver, spleen and other organs.

The rare pediatric disease designation is granted to drugs that have the potential to treat orphan diseases affecting fewer than 200,000 patients in the U.S. and with more than 50% of those affected age 18 years or younger.

The medication is undergoing a phase 1 trial in the U.S. and a phase 1/2 trial in Europe and Israel. The company recently filed an application to conduct a clinical trial in Italy.

The treatment earlier secured orphan drug designations in the U.S. and the European Union.